Evidence map›Paper›PMID 38612996›Full record

ReviewNutrients2024

Omega-3 (

Ivana Djuricic, Philip C Calder

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Lipid metabolism, microglia, and stroke.Neural regeneration research · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. α-ALA Attenuates Cardiac Injury in Diabetic Heart Disease Mice by Modulating Inflammation and AMPKα1.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Ivana DjuricicDepartment of Bromatology, Faculty of Pharmacy, University of Belgrade, 11221 Belgrade, Serbia.
Philip C CalderSchool of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.ORCID 0000-0002-6038-710X
University Hospital Southampton NHS Foundation Trust · GBUniversity of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Managing atherosclerotic cardiovascular disease (ASCVD) often involves a combination of lifestyle modifications and medications aiming to decrease the risk of cardiovascular outcomes, such as myocardial infarction and stroke. The aim of this article is to discuss possible omega-3 (

Indexed as

AtherosclerosisCardiovascular DiseasesFatty Acids, Omega-3Hydroxymethylglutaryl-CoA Reductase InhibitorsDocosahexaenoic AcidsEicosapentaenoic AcidFatty AcidsHumansInflammationDocosahexaenoic AcidsEicosapentaenoic AcidFatty AcidsFatty Acids, Omega-3Hydroxymethylglutaryl-CoA Reductase InhibitorsASCVDinflammationlipid loweringn-3 fatty acidSPMstatin

Identifiers

PMID38612996
PMCPMC11013773
OpenAlexW4393235462

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.